Australian Clinical Labs Ltd (AU:ACL) has released an update.
JPMorgan Chase & Co. and its affiliates have increased their voting power in Australian Clinical Labs Ltd from 6.36% to 7.48% through various transactions, as detailed in a recent substantial holding notice. The changes occurred between the last notice and July 10, 2024, involving purchases, sales, and securities lending agreements, affecting over a million ordinary shares.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.
